Inspire Medical Systems, Inc. (INSP)
| Previous close | 248.35 |
| Open | 235.51 |
| Bid | 244.52 x 800 |
| Ask | 252.56 x 800 |
| Day's range | 251.14 - 253.80 |
| 52-week range | 142.74 - 282.31 |
| Volume | |
| Avg. volume | 308,688 |
| Market cap | 7.393B |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.59 |
| Earnings date | 01 May 2023 - 05 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 305.89 |
- Simply Wall St.
Inspire Medical Systems, Inc. (NYSE:INSP): When Will It Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at Inspire Medical Systems...
- GlobeNewswire
Inspire Medical Systems, Inc. Announces FDA Approval for Pediatric Patients with Down Syndrome
MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced today that it has received approval from the Food and Drug Administration (FDA) to offer Inspire therapy to pediatric patients with Down syndrome. “Since our first FDA approval in 2014, the research team at Mass Eye a
- GlobeNewswire
Inspire Medical Systems, Inc. Announces Countrywide Reimbursement in Belgium
MINNEAPOLIS, March 09, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced today that it has received countrywide reimbursement approval in Belgium, effective immediately, at rates consistent with other countries around the world. “The healthcare team at Antwerp University Hospital (UZA) in
